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OBJECTIVES The purpose of this study was to assess the tolerability and efficacy of carvedilol in patients
with New York Heart Association (NYHA) functional class IV symptoms.
BACKGROUND Carvedilol, a nonselective beta-adrenergic blocking drug with alpha-adrenergic blocking and
antioxidant properties, has been shown to improve left ventricular function and clinical
outcome in patients with mild to moderate chronic heart failure.
METHODS We retrospectively analyzed the outcomes of 230 patients with heart failure treated with
carvedilol who were stratified according to baseline functional class: 63 patients were NYHA
class IV and 167 were NYHA class I, II or III. Carvedilol was commenced at 3.125 mg b.i.d.
and titrated to 25 mg b.i.d. as tolerated. Patients with class IV symptoms were older (p 5
0.03), had lower left ventricular fractional shortening (p , 0.001), had lower six-min walk
distance (p , 0.001) and were receiving more heart failure medications at baseline compared
with less symptomatic patients.
RESULTS Nonfatal adverse events while taking carvedilol occurred more frequently in class IV patients
(43% vs. 24%, p , 0.0001), and more often resulted in permanent withdrawal of the drug
(25% vs. 13%, p , 0.01). Thirty-seven (59%) patients who were NYHA class IV at baseline
had improved by one or more functional class at 3 months, 8 (13%) were unchanged and 18
(29%) had deteriorated or died. Among the less symptomatic group, 62 (37%) patients had
improved their NYHA status at 3 months, 73 (44%) were unchanged and 32 (19%) had
deteriorated or died. The differences in symptomatic outcome at three months between the
two groups were statistically significant (p 5 0.001, chi-square analysis). Both groups
demonstrated similar significant improvements in left ventricular dimensions and systolic
function.
CONCLUSIONS Patients with chronic NYHA class IV heart failure are more likely to develop adverse events
during initiation and dose titration when compared with less symptomatic patients but are
more likely to show symptomatic improvement in the long term. We conclude that carvedilol
is a useful adjunctive therapy for patients with NYHA class IV heart failure; however, they
require close observation during initiation and titration of the drug. (J Am Coll Cardiol 1999;
33:924–31) © 1999 by the American College of Cardiology
Traditionally, beta-adrenergic blocking agents have been
considered contraindicated in patients with heart failure due
to short-term adverse effects; however, there is clinical
evidence dating back to the 1970s that these drugs may be
beneficial in selected patients (1,2). These and more recent
studies have reported a range of benefits including improved
systolic function (1,3–7), improved symptomatic status
(3,8,9) and reduced hospitalization (10,11). Furthermore,
meta-analyses of the randomized clinical trials of beta-
blockers in heart failure suggest that this class of drugs
reduces mortality in heart failure by about 35% when added
to angiotensin-converting enzyme inhibitors (12,13).
The largest clinical trial experience reported for any
beta-blocker in heart failure has been obtained with carve-
dilol, a nonselective beta-blocker with alpha-blocking and
antioxidant properties. In addition to the clinical benefits
described above, carvedilol has been shown to produce
reverse remodeling of the dilated left ventricle (7) and to
delay progression of mild heart failure (14). The random-
ized clinical trials of carvedilol in heart failure have been
conducted predominantly in patients with mild to moderate
symptomatic heart failure. As shown in Table 1, only 37 of
1,672 patients entered into randomized studies of carvedilol
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in heart failure were New York Heart Association (NYHA)
class IV at baseline (5,8–11). Currently, there is very limited
information regarding the safety and efficacy of carvedilol or
other beta-blockers in patients with severe symptomatic
heart failure, that is, those who are in NYHA functional
class IV at the time the drug is commenced.
The primary goal of this study was to assess the tolera-
bility and efficacy of carvedilol in chronic heart failure
patients who were established in NYHA functional class IV
at the time of its initiation. A secondary goal was to
determine if there were any baseline characteristics that
discriminated between those class IV patients who tolerated
carvedilol from those who did not.
METHODS
Patient population. We retrospectively analyzed the out-
comes of 230 patients who received carvedilol for the
treatment of chronic heart failure. All patients included in
this analysis were attending a Heart Failure and Heart
Transplant Assessment Clinic at our institution and had
been receiving heart failure therapy for at least three months
before commencement of carvedilol. All patients had left
ventricular systolic dysfunction at baseline as defined by a
left ventricular fractional shortening of less than 28% on
echocardiography. Patients were not considered for carve-
dilol if they had any of the following at baseline assessment:
cardiogenic shock, intractable pulmonary or systemic
edema, heart failure requiring intravenous inotropic or
mechanical support, bradycardia with heart rate less than 50
beats/min, systemic hypotension with blood pressure less
than 80/50 mm Hg or chronic airflow limitation with
evidence of 20% or greater reversibility in airways obstruc-
tion in response to inhaled salbutamol. Apart from these
exclusions, all class IV patients referred to our Heart Failure
Clinic were challenged with carvedilol.
Carvedilol administration. Throughout the duration of
this study, carvedilol was available as an investigational
agent for the treatment of heart failure (Special Access
Scheme of the Therapeutic and Goods Administration
Division of the Australian Department of Health). Its use
for this indication was approved by the St. Vincent’s
Hospital Human Ethics and Research Committee. The
decision to use carvedilol was at the discretion of the
attending cardiologist (P.S.M. or A.M.K.). Carvedilol was
commenced in a dose of 3.125 mg b.i.d. The dose of
carvedilol was doubled at two weekly intervals as tolerated
up to a target dose of 25 mg b.i.d.
Assessment and follow-up. All patients underwent clinical
assessment at baseline, one month and then every three
months after commencement of carvedilol. This included an
evaluation of NYHA functional status and physical exami-
nation including measurement of supine resting heart rate
and blood pressure. Patient symptomatic outcome was
graded at each follow-up evaluation as “improved,” “un-
changed” or “worse” according to changes in NYHA status.
Patients who died, were transplanted or who were unable to
tolerate carvedilol were considered “worse.” An echocardio-
gram and 6-min walk test were performed at baseline, and
3-month and 12-month follow-up. Left ventricular (LV)
dimensions were made using two-dimensionally guided
M-mode echocardiography according to the American So-
ciety of Echocardiography standards for LV dimensions
(15). Left ventricular ejection fraction was calculated from
echocardiographic M-mode dimensions using the formula
of Teichholz (16). In addition, the following major clinical
events were recorded: worsening heart failure resulting in
hospitalization or prolongation of hospitalization, hospital-
ization for any other reason, heart transplantation and
death.
Statistical analysis. Unless otherwise stated data are pre-
sented as mean 6 standard error of the mean. Comparisons
between classes were made using factorial analysis of vari-
ance (ANOVA) for continuous variables and chi-square
analyses for categorical variables. For continuous variables in
which the p value was ,0.05 by ANOVA, post hoc analyses
with unpaired t tests using Bonferroni correction were used
to detect differences between individual classes. Compari-
sons between the less symptomatic group and the class IV
patients were made using unpaired t tests for continuous
variables and chi-square analyses for categorical variables.
Kaplan–Meier cumulative survival curves were constructed
for each group to compare mortality and the incidence of
adverse events. Differences between Kaplan–Meier curves
were tested for significance using the Mantel–Cox log-rank
test. A p value ,0.05 was considered significant.
Abbreviations and Acronyms
ANOVA 5 analysis of variance
ANZ 5 Australia and New Zealand
LV 5 left ventricular
LVEDD 5 left ventricular end-diastolic dimension
LVESD 5 left ventricular end-systolic dimension
NYHA 5 New York Heart Association
Table 1. Studies of Carvedilol in Heart Failure
Study
No. of
Patients
NYHA
Class IV
Patients
Metra et al. (5) 40 0
Olsen et al. (8) 60 0
Krum et al. (9) 65 5
ANZ Study (11) 415 0
U.S. Carvedilol Heart Failure
Program (10)
1,094 32
Total 1,674 37
ANZ 5 Australia and New Zealand; NYHA 5 New York Heart Association.
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RESULTS
Patient population. The distribution of patients according
to baseline NYHA functional class at the time of initiation
of carvedilol and selected baseline characteristics for the
study population are shown in Table 2. Compared with the
less symptomatic patients, those with NYHA class IV heart
failure at baseline were significantly older and were more
likely to have ischemic heart disease. They had lower
fractional shortening and ejection fraction as assessed by
echocardiography. In addition, they had a significantly
lower baseline 6-min walk distance. The use of digoxin and
direct acting vasodilators was significantly higher in NYHA
class IV patients. Overall, just one third of patients were
receiving amiodarone therapy at baseline with no significant
difference between the class IV and the less symptomatic
patients. There were also nonsignificant trends toward a
higher resting heart rate and larger LV end-systolic dimen-
sion in the class IV patients.
In subsequent analyses, the 167 patients who were
NYHA functional class I, II or III (less symptomatic group)
were compared with the remaining 63 patients in NYHA
functional class IV heart failure. The mean duration of
follow-up was 365 days (range: 96 to 749 days). The average
maintenance dose of carvedilol was 32 6 2 mg per day in
the less symptomatic group versus 36 6 2 mg per day in the
class IV group (p 5 NS).
Actuarial survival. Actuarial survival for the two groups is
shown in Figure 1. One-year actuarial survival for the less
symptomatic group was 94 6 2% compared with 84 6 5%
for the NYHA class IV patients (p , 0.01). Actuarial
transplant-free survival for the less symptomatic group was
90 6 3% at one year compared with 77 6 6% for the
NYHA class IV patients (p , 0.001).
Tolerability of carvedilol—adverse events. Serious ad-
verse events excluding death or transplantation occurred in
24% of the less symptomatic group compared with 43% of
class IV patients (p , 0.0001) and resulted in permanent
withdrawal of carvedilol in 13% and 25%, respectively.
Nonfatal adverse events are summarized in Table 3. The
major difference between the two groups was in the higher
rate of worsening heart failure in the class IV patients
compared with the less symptomatic patients. Worsening
heart failure occurred in 16 (10%) of the less symptomatic
group and 14 (21%) of the class IV group (p , 0.05);
however, carvedilol was able to be resumed or continued in
Table 2. Selected Baseline Characteristics
Characteristic
Class I
(n 5 10)
Class II
(n 5 45)
Class III
(n 5 112)
Class IV
(n 5 63)
Age (yr) 45 6 1 52 6 2 54 6 1 57 6 2*
Gender (% male) 90 84 84 89
Diagnosis (CM:IHD:other) 8:2:0 28:14:3 67:35:10 27:32:4*
Duration (months) 30 6 12 30 6 5 33 6 6 28 6 4
Heart rate (beats/min) 83 6 5 79 6 2 82 6 2 86 6 2
Echocardiographic measurements
LVEDD (mm) 77 6 3 73 6 2 72 6 1 75 6 1
LVESD (mm) 64 6 5 62 6 2 62 6 1 67 6 2
FS (%) 18 6 3 15 6 1 14 6 1 11 6 1†
EF (%) 29 6 5 26 6 1 24 6 1 19 6 1†
6-min walk (m) 580 6 31 513 6 13 417 6 10‡ 321 6 16†
Treatment (%)
ACE inhibitors 100 98 97 97
Diuretics 70 80 96 97
Digoxin 50 60 79 89*
Vasodilators 10 38 53 67*
Antithrombotic 60 67 82 80
Amiodarone 20 31 40 35
*p , 0.05 class IV vs. other classes. †p , 0.001 class IV vs. other classes. ‡p , 0.005 class III vs. classes I or II.
ACE 5 angiotensin-converting enzyme; CM 5 cardiomyopathy; EF 5 ejection fraction; FS 5 fractional shortening;
IHD 5 ischemic heart disease; LVEDD 5 left ventricular end-diastolic dimension; LVESD 5 left ventricular end-systolic
dimension.
Figure 1. Cumulative survival stratified according to baseline New
York Heart Association (NYHA) class (NYHA classes I to III
have been analyzed as a single group).
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11 of these patients (eight less symptomatic and three class
IV patients) after adjustment of concomitant antifailure
therapy.
Symptomatic bradyarrhythmias occurred in only 3% of
patients with no difference between class IV and less
symptomatic patients. Concurrent amiodarone therapy,
which was used in approximately one third of all patients,
did not increase the incidence of bradyarrhythmias.
Figure 2 shows the actuarial freedom from adverse events
in the two patient groups. Most adverse events occurred
within the first six weeks of commencement of carvedilol
therapy with more than half occurring during the first two
weeks, when patients were receiving the lowest dose of
carvedilol.
Predictors of adverse events in class IV heart failure
patients. Table 4 shows a comparison of selected baseline
variables between NYHA class IV patients who experienced
an adverse event during follow-up and those who did not.
Two variables differed significantly between the two groups
on univariate analysis. Class IV patients who experienced an
adverse reaction attributable to carvedilol had a significantly
lower systolic blood pressure and lower serum sodium at
baseline compared with patients who did not (Table 4).
Linear regression analysis revealed a highly significant
relationship between serum Na1 and systolic blood pressure
(p , 0.001). Serum Na1 was the most potent predictor of
an adverse event. Fifteen of 24 (63%) patients who were
hyponatremic (serum Na1 ,137 mmol/liter) at baseline
experienced an adverse event during follow-up compared
with 8 of 39 (20%) class IV patients who had a normal
serum Na1 level at baseline (p , 0.002).
Efficacy of carvedilol—symptomatic outcome. Symp-
tomatic outcome data were available on all patients after 3
months; 37 (59%) of 63 patients who were NYHA class IV
at baseline had improved by one or more functional class at
3 months, 8 (12%) were unchanged and 18 (29%) had
deteriorated or died. Of the 37 NYHA class IV patients
who improved at 3 months, 21 improved to NYHA class
III, 13 improved to NYHA class II and 3 improved to
NYHA class I. Among the less symptomatic group, 63
(37%) of 167 patients had improved their NYHA status at
3 months, 73 (44%) were unchanged and 32 (19%) had
deteriorated or died. The differences in symptomatic out-
come at 3 months between the two groups were statistically
significant (p 5 0.001, chi-square analysis). The differences
in symptomatic outcome between the two groups were
unaffected by exclusion of seven patients (three class IV and
four class III) who underwent heart transplantation within
three months of commencing carvedilol.
Increases in concomitant heart failure therapy (predom-
inantly diuretic dosage) during the first three months of
carvedilol treatment were made in 15% of the less symp-
tomatic group and 22% of the class IV group (p 5 NS
compared with the less symptomatic group). Increases in
concomitant therapy were made predominantly in those
patients whose symptomatic status worsened during carve-
Table 3. Nonfatal Adverse Events
Adverse Event
NYHA
Classes I–III
(n 5 167)
NYHA Class
IV
(n 5 63)
Worsening heart failure 16 (10%) 14 (22%)
Lethargy 4 (2%) 2 (3%)
Bradyarrhythmia 5 (3%) 2 (3%)
Tachyarrhythmia 2 (1%) 2 (3%)
Hypotension 6 (4%) 3 (5%)
Acute myocardial infarction 1 (1%) 1 (2%)
Headache 2 (1%) 1 (2%)
Aggressive behavior 1 (1%) 0 (0%)
TIA 1 (1%) 0 (0%)
Pneumonia 1 (1%) 1 (2%)
Anorexia 0 (0%) 1 (2%)
Acute renal failure 1 (1%) 0 (0%)
Total 40 (24%) 27 (43%)
NYHA 5 New York Heart Association; TIA 5 transient ischemic attack.
Figure 2. Cumulative freedom from adverse reactions stratified
according to baseline New York Heart Association (NYHA) class
(NYHA classes I to III have been analyzed as a single group).
Solid bar indicates initiation and titration of carvedilol.
Table 4. Adverse Events on Carvedilol (NYHA
Class IV Patients)
Variable
No
(n 5 36)
Yes
(n 5 27)
p
Value
Age (yr) 61 6 2 54 6 3 NS
Gender (% male) 91 86 NS
Diagnosis (CM:IHD:other) 14:18:5 12:14:1 NS
Heart rate (beats/min) 84 6 2 85 6 2 NS
Systolic BP (mm Hg) 108 6 3 97 6 3 0.024
Diastolic BP (mm Hg) 70 6 2 62 6 2 0.009
Mean BP (mm Hg) 82 6 2 74 6 2 0.01
Echo LVEDD (mm) 75 6 2 74 6 3 NS
Echo LVESD (mm) 67 6 3 65 6 3 NS
Echo FS (%) 11 6 1 11 6 1 NS
Echo EF (%) 19 6 1 19 6 2 NS
6-min walk (m) 330 6 27 309 6 23 NS
Serum Na1 (mmol/liter) 138 6 1 136 6 0 0.0026
BP 5 blood pressure. Other abbreviations as in Tables 1 and 2.
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dilol treatment. Only 2 of 99 patients who improved during
the first 3 months of carvedilol treatment (one in each
group) were receiving increased concomitant heart failure
therapy after 3 months.
Efficacy of carvedilol—left ventricular dimensions and
systolic function. The effect of carvedilol on left ventricu-
lar dimensions at three months as assessed by echocardiog-
raphy is shown in Figure 3. Paired baseline and 3-month
echocardiograms suitable for comparative analysis were
obtained in 163 (86%) of 190 patients who continued on
carvedilol beyond 3 months. Left ventricular end-systolic
dimension (LVESD) decreased significantly in both groups
after 3 months of carvedilol treatment; mean LVESD fell by
4.0 6 1.0 mm in NYHA class IV patients (n 5 41, p ,
0.0005 compared with baseline) and by 3.3 6 0.6 mm in
NYHA class I–III patients (n 5 122, p , 0.0001 compared
with baseline). Left ventricular end–diastolic dimension
(LVEDD) also decreased, but the difference only achieved
significance in the less symptomatic group; mean LVEDD
fell by 1.3 6 0.9 mm in NYHA class IV patients (n 5 41,
p 5 NS compared with baseline) and by 1.7 6 0.5 mm in
NYHA class I–III patients (n 5 122, p , 0.002 compared
with baseline). The magnitude of the changes in LVESD
and LVEDD over three months did not differ significantly
between the class IV patients and the class I–III patients.
The reductions in LV dimensions observed after three
months of carvedilol therapy were accompanied by highly
significant increases in left ventricular fractional shortening
and calculated ejection fraction in both treatment groups
with no significant difference between groups (Fig. 4). Left
ventricular fractional shortening increased by 2.8 6 0.6% in
the less symptomatic group (n 5 122, p , 0.0001 compared
with baseline) and 4.0 6 0.9% in the class IV patients (n 5
41, p , 0.0001 compared with baseline). Corresponding
increases in calculated LV ejection fraction were 4.7 6 0.9%
and 6.9 6 1.5%, respectively.
Efficacy of carvedilol— 6-min walk distance. The effect
of carvedilol on 6-min walk distance is shown in Figure 5.
The 6-min walk distance improved by 38 6 7 meters (n 5
121, p , 0.001 compared with baseline) in the less symptom-
atic patients and by 76 6 18 meters (n 5 39, p 5 0.0002
compared with baseline) in the NYHA class IV patients.
DISCUSSION
Tolerability of carvedilol. The primary finding of this
study was that carvedilol was tolerated by most heart failure
patients who were NYHA class IV at the time of initiation
of carvedilol. Overall, 71% of this group tolerated long-term
carvedilol treatment, with 59% showing symptomatic im-
Figure 3. Change in left ventricular (LV) end-diastolic dimension
(solid bar) and end-systolic dimension (hatched bar) after three
months of therapy with carvedilol. **p , 0.002, ****p , 0.0001
compared with baseline. Paired data were obtained in 122 New
York Heart Association (NYHA) class I–III patients and 41 class
IV patients.
Figure 4. Change in left ventricular fractional shortening (solid
bar) and ejection fraction (hatched bar) after 3 months of therapy
with carvedilol. ****p , 0.0001 compared with baseline. Paired
data were obtained in 122 New York Heart Association (NYHA)
class I–III patients and 41 class IV patients.
Figure 5. Change in 6-min walk distance after 3 months of
therapy with carvedilol. Open circles 5 New York Heart Asso-
ciation classes I to III (n 5 121); solid circles 5 class IV (n 5 39).
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provement by three months. This improvement in symp-
toms was associated with significant improvements in LV
dimensions and contraction as assessed by echocardiography
and in 6-min walk distance. It is important to emphasize
that not all class IV patients were commenced on carvedilol.
In particular, patients were not considered for carvedilol if
they were in cardiogenic shock, or had intractable pulmo-
nary or systemic edema or heart failure requiring intrave-
nous inotropic support or mechanical support. In addition,
patients were excluded if they had a resting bradycardia with
heart rate less than 50 beats per minute, systemic hypoten-
sion with blood pressure less than 80/50 mm Hg or asthma.
Apart from these exclusions, all class IV patients referred to
our heart failure clinic were challenged with carvedilol. We
believe that the class IV patients whom we enrolled were
broadly representative of class IV patients referred to our
center and were not a highly selected group. The mean
systolic blood pressure for the class IV patients at baseline
was 101 mm Hg, and 40% were hyponatremic or had a
systolic blood pressure less than 90 mm Hg at the time of
initiation of carvedilol.
As expected, carvedilol was better tolerated by the less
symptomatic group of heart failure patients. We found that
approximately 90% of heart failure patients who were
NYHA class I–III at baseline tolerated long-term carve-
dilol. This experience is consistent with that of the U.S.
Heart Failure Program (10) and the Australia and New
Zealand (ANZ) Study Group (11), both of whom studied
similar patient populations. Packer et al. (10) reported that
1.4% of patients did not tolerate open-label run-in, and a
further 5.7% were withdrawn after randomization due to
adverse events. In the ANZ Study (11), 3.6% of patients did
not tolerate open-label run-in, and 14% of patients were
withdrawn from carvedilol after randomization. In a study
of patients with more severe heart failure, most of whom
were class III at baseline, Krum et al. (9) reported that
12.5% of patients died or were withdrawn from carvedilol
during open-label run-in, and 37% developed worsening
heart failure after randomization. When considered in
relation to the present findings, these results indicate that
the likelihood of serious adverse events necessitating with-
drawal of carvedilol increases with increasing NYHA func-
tional class at baseline. Nonetheless, our findings suggest
that carvedilol is a useful adjunctive therapy in selected
NYHA class IV patients, some of whom show dramatic
symptomatic improvement.
Adverse events. The major difference in nonfatal adverse
events between the class IV and the less symptomatic
patients was the more than twofold increase in the incidence
of worsening heart failure in the former group. If patients
developed adverse symptoms during initiation and titration
of carvedilol therapy, we attempted to adjust concurrent
therapies to allow continuation of carvedilol. In general,
worsening heart failure was treated with either an increased
diuretic or nitrate therapy. Further up-titration of carvedilol
was only attempted after the symptoms and signs of
worsening heart failure resolved completely. Approximately
one third of patients who developed worsening heart failure
on carvedilol were able to be maintained on the drug
chronically. Sackner-Bernstein et al. (17) have reported that
such patients have a similar favorable long-term outcome to
patients who tolerate carvedilol at the first attempt.
Other recognized adverse reactions to carvedilol therapy,
namely symptomatic bradycardia, hypotension and fatigue,
were infrequent and occurred with similar frequency in the
two groups. Most adverse events occurred during initiation
and titration of carvedilol. This occurred despite com-
mencement of carvedilol at a dose of only 3.125 mg twice
daily. Indeed, more than half the adverse events occurred
during the first two weeks of carvedilol therapy. Clearly,
patients with NYHA class IV heart failure require close
observation during initiation of carvedilol. The class IV
patients who were at most risk of adverse events were those
who were hyponatremic at the time of commencement of
carvedilol. Sackner-Bernstein et al. (17) also found that
hyponatremia was the most powerful predictor of adverse
events after initiation of carvedilol in patients with moderate
to severe heart failure. This is not surprising. Hyponatremia
has been shown to correlate closely with neurohormonal
activation in heart failure, particularly of the renin–
angiotensin system (18), and is an independent predictor of
mortality in patients with severe heart failure (19,20).
Furthermore, as noted in the present study, hyponatremic
patients are more likely to be hypotensive (18,19). They are
also more likely to have evidence of impaired peripheral and
renal perfusion than class IV heart failure patients with
normal serum sodium (18,19). Our current policy is to
admit all class IV patients with hyponatremia or hypoten-
sion to hospital during initiation of carvedilol.
Symptomatic outcome. Our findings with regard to the
effect of carvedilol on symptomatic status in class I–III heart
failure at three months are consistent with those reported in
the ANZ Study at six months (21). In the ANZ Study, 23%
had improved, 65% were unchanged and 12% had deterio-
rated by six months. In comparison, 33% of patients
improved, 45% were unchanged and 23% deteriorated after
three months of carvedilol therapy in our study. In contrast,
class IV patients as a group tended to either improve or
deteriorate on carvedilol. Although the hazards of carvedilol
are clearly greatest in class IV patients, this group potentially
has the most to gain from this therapy, because more than
half improved their symptomatic status after three months
of therapy. The improvement in symptomatic status after
initiation of carvedilol cannot be attributed to changes in
concomitant heart failure therapy, because only 2 of 99
patients who had improved their symptomatic status after 3
months of carvedilol treatment were receiving increased
doses of concomitant heart failure medications.
Left ventricular size and function. Several studies have
demonstrated a favorable effect of carvedilol on left ventric-
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ular dimensions (11,21) and LV systolic function (5,6,8,11)
in patients with chronic heart failure. Our study demon-
strates that these beneficial effects of carvedilol extend to
class IV patients. Furthermore the magnitude of the im-
provement observed in class IV patients is comparable to
that observed in the less symptomatic patients. This finding
provides a further rationale for the use of carvedilol in these
patients, as Packer et al. (22) have recently reported that the
clinical benefits of carvedilol noted in the U.S. Carvedilol
Heart Failure Program were closely correlated with the
drug’s beneficial effects on LV systolic function.
Six-minute walk distance. Previous studies have reported
conflicting results regarding the effects of carvedilol and
other beta-blocking drugs on exercise performance in pa-
tients with heart failure (23). In view of the well recognized
ability of beta-blockers to attenuate exercise-induced in-
creases in heart rate (24), Krum et al. (9) have suggested that
submaximal rather than maximal exercise performance may
provide a more accurate assessment of the effect of beta-
blockade on functional capacity in patients with heart
failure; however, the effects of carvedilol on this parameter
have also been conflicting (5,8,9,21). One possible explana-
tion for this discrepancy is the difference in baseline symp-
tomatic status between studies. Studies that recruited pa-
tients with milder symptoms (8,21) have generally failed to
show a significant improvement in submaximal exercise
performance, whereas studies with a greater proportion of
more symptomatic patients (5,9) have shown a positive
treatment effect. Overall, we found that heart failure pa-
tients significantly improved their 6-min walk distance after
three months of carvedilol treatment. The average increase
in walk distance seen in the less symptomatic group after
three months was very similar to that reported by Krum et
al. (9). The class IV patients showed an even greater
increase in 6-min walk distance than the less symptomatic
group. This latter result may have been biased by the greater
dropout of class IV patients who failed to tolerate carvedilol
and who therefore did not undergo a second 6-min walk test
at three months.
Actuarial survival. The one-year mortality in the class
I–III group was only 6 6 3%. This is similar to the mortality
rate reported for comparable patients receiving carvedilol
reported in the U.S. Heart Failure program (10) and the
ANZ Carvedilol Study (11). Not surprisingly, mortality was
higher in the class IV patients than in the less symptomatic
group. In the absence of a matched control group it is not
possible to determine the impact of carvedilol on mortality
in class IV patients; however, the one-year mortality of 16 6
5% in this patient group treated with carvedilol compares
favorably with the mortality reported for similar patient
groups in other studies (19,25–27). The impact of carvedilol
on mortality in patients with NYHA class IV heart failure is
currently being addressed in the ongoing Copernicus Study.
Study limitations. The major limitations of this study were
the lack of a control group and the open-label administra-
tion of carvedilol. We can only speculate regarding the
extent to which placebo response and observer (patient and
doctor) bias contributed to the observed benefits of carve-
dilol in our patients, particularly with respect to the im-
proved 6-min walk distance that we observed; however, the
other outcomes that we observed in the class I–III patients
were highly consistent with what has been reported previ-
ously in placebo-controlled randomized studies.
The greater tendency for the class IV patients to improve
their symptomatic status after the initiation of carvedilol
compared with the less symptomatic patients may simply
reflect an inherent bias in the analysis. Class IV patients
could only feel better and not worse. At the other end of the
spectrum, class I patients could only deteriorate, whereas
class II and III patients could either improve or worsen their
symptomatic status. We attempted to address this bias by
categorizing all patients who died, underwent transplanta-
tion or failed to tolerate carvedilol as having a worse
functional outcome; 29% of class IV patients fell into this
category.
Another limitation is the relatively young age of our heart
failure population compared with the average age of heart
failure patients in the general community (28). We did not
exclude any patients for carvedilol therapy because of age
and believe that the relatively young age of the patients
reported in this series simply reflects the referral bias toward
younger patients to our transplant program. Forty-three
patients in this series were over 65 years of age at the time
of commencement of carvedilol. After adjusting for differ-
ences in baseline functional class, we did not observe any
difference in their response to carvedilol compared with the
younger patients (data not shown). Fisher et al. (29) have
also reported that beta-blockers are well tolerated by elderly
heart failure patients.
Conclusions. Most patients with chronic NYHA class IV
heart failure tolerate carvedilol and show benefits in both by
symptomatic status and left ventricular size and function
three months of therapy. As a group, they are more likely to
develop adverse events during initiation and dose titration,
when compared with less symptomatic patients, but are
more likely to show symptomatic improvement in the long
term. The risk of adverse events is particularly high in class
IV patients who are hyponatremic at the initiation of
carvedilol. We conclude that carvedilol is a useful adjunctive
therapy for patients with NYHA class IV heart failure;
however, they require close observation during initiation
and titration of the drug.
Acknowledgment
Carvedilol was kindly supplied by SmithKline Beecham
International, a division of SmithKline Beecham (Mel-
bourne, Australia) Pty Ltd.
930 Macdonald et al. JACC Vol. 33, No. 4, 1999
Carvedilol in NYHA Class IV Heart Failure March 15, 1999:924–31
Reprint requests and correspondence: Associate Professor Peter
Macdonald, Heart & Lung Transplant Unit, St. Vincent’s Hospital,
Darlinghurst, NSW, 2010 Australia. E-mail: pmacdonald@stvincents.
com.au.
REFERENCES
1. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I.
Effect of chronic beta-adrenergic receptor blockade in conges-
tive cardiomyopathy. Br Heart J 1975;37:1022–36.
2. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I.
Prolongation of survival in congestive cardiomyopathy by
beta-receptor blockade. Lancet 1979;i:1374–6.
3. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial
effects of metoprolol in idiopathic dilated cardiomyopathy.
Metroprolol in Dilated Cardiomyopathy (MDC) Trial Study
Group (see comments). Lancet 1993;342:1441–6.
4. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects
of metoprolol in heart failure associated with coronary artery
disease: a randomized trial. J Am Coll Cardiol 1994;23:943–
50.
5. Metra M, Nardi M, Giubbini R, Cas LD. Effects of short-
and long-term carvedilol administration on rest and exercise
hemodynamic variables, exercise capacity and clinical condi-
tions in patients with idiopathic dilated cardiomyopathy. J Am
Coll Cardiol 1994;24:1678–87.
6. Bristow M, Gilbert E, Abraham W, et al. Carvedilol produces
dose-related improvements in left ventricular function and
survival in subjects with chronic heart failure. Circulation
1996;94:690–7.
7. Doughty R, Whalley G, Gamble G, et al. Left ventricular
remodeling with carvedilol in patients with congestive heart
failure due to ischemic heart disease. J Am Coll Cardiol
1997;29:1060–6.
8. Olsen S, Gilbert E, Renlund D, Taylor D, Yanowitz F,
Bristow M. Carvedilol improves left ventricular function and
symptoms in chronic heart failure: a double-blind randomized
study. J Am Coll Cardiol 1995;25:1225–31.
9. Krum H, Sackner-Bernstein J, Goldsmith R, et al. Double-
blind, placebo-controlled study of the long-term efficacy of
carvedilol in patients with severe chronic heart failure. Circu-
lation 1995;92:1499–506.
10. Packer M, Bristow M, Cohn J, et al. The effect of carvedilol
on morbidity and mortality in patients with chronic heart
failure. N Engl J Med 1996;334:1349–55.
11. Australia-New Zealand Heart Failure Research Collaborative
Group. Randomised, placebo-controlled trial of carvedilol in
patients with congestive heart failure due to ischaemic heart
disease. Lancet 1997;349:375–80.
12. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of
beta-blocker therapy on mortality in patients with heart
failure. A systematic overview of randomized controlled trials.
Eur Heart J 1997;18;560–5.
13. Heidenreich PA, Lee TT, Massie BM. Effect of beta-
blockade on mortality in patients with heart failure: a meta-
analysis of randomized clinical trials. J Am Coll Cardiol
1997;30:27–34.
14. Colucci W, Packer M, Bristow M, et al. Carvedilol inhibits
clinical progression in patients with mild symptoms of heart
failure. Circulation 1996;94:2800–6.
15. Sahn D, DeMaria A, Kisslo J, et al. Recommendations
regarding quantitation in M-mode echocardiography: results
of a survey of echocardiographic measurements. Circulation
1978;58:1072–82.
16. Teichholz L, Kreulen T, Herman M, Gorlin R. Problems in
echocardiographic volume determinations: echocardiographic-
angiographic correlations in the presence and absence of
asynergy. Am J Cardiol 1976;37:7–11.
17. Sackner-Bernstein J, Krum H, Goldsmith R, et al. Should
worsening heart failure early after initiation of beta-blocker
therapy for chronic heart failure preclude long-term treatment
(abstr). Circulation 1995;92 Suppl 1:I-395.
18. Dzau V, Colucci W, Hollenberg N, Williams G. Relation of
the renin-angiotensin-aldosterone system to clinical state in
congestive heart failure. Circulation 1981;63:645–51.
19. Lee W, Packer M. Prognostic importance of serum sodium
concentration and its modification by converting enzyme
inhibition in patients with severe chronic heart failure. Circu-
lation 1986;73:257–67.
20. Parameshwar J, Keegan J, Sparrow J, Sutton G, Poole-Wilson
P. Predictors of prognosis in severe chronic heart failure. Am
Heart J 1992;123:421–6.
21. Australia-New Zealand Heart Failure Research Collaborative
Study. Effects of carvedilol, a vasodilator-beta-blocker, in
patients with congestive heart failure due to ischaemic heart
disease. Circulation 1995;92:212–8.
22. Packer M, Colucci W, Cohn J, et al. Relationship between
long-term changes in left ventricular function and clinical
outcome in patients with chronic heart failure treated with
carvedilol. J Am Coll Cardiol 1997;29:64A.
23. Eichhorn E. The paradox of beta-adrenergic blockade for the
management of congestive heart failure. Am J Med 1992;92:
527–38.
24. Tesch P. Exercise performance and b-blockade. Sports Med
1985;2:389–412.
25. Franciosa J, Wilen M, Ziesche S, Cohn J. Survival in men
with severe chronic left ventricular failure due to either
coronary heart disease or idiopathic dilated cardiomyopathy.
Am J Cardiol 1983;51:831–6.
26. The CONSENSUS Trial Study Group. Effects of enalapril
on mortality in severe congestive heart failure: results of the
Co-operative North Scandinavian Enalapril Survival Study.
N Engl J Med 1987;316:1429–35.
27. Keogh A, Baron D, Hickie J. Prognostic guides in patients
with idiopathic or ischemic dilated cardiomyopathy assessed
for cardiac transplantation. Am J Cardiol 1990;65:903–8.
28. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am
Heart J 1991;121:951–7.
29. Fisher M, Gottlieb S, Bennett S. Response to b-blocker in
elderly patients with severe heart failure (abstract). J Am Coll
Cardiol 1997;29:465A.
931JACC Vol. 33, No. 4, 1999 Macdonald et al.
March 15, 1999:924–31 Carvedilol in NYHA Class IV Heart Failure
